PharVision Advisers’s Credicorp BAP Stock Holding History

PharVision Advisers’s Portfolio BAP Stock Details BAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,045	Closed	-$278K	–	706
2025 Q3	$278K	Buy	+1,045	New	+$259K	0.16%	272

Other funds holding BAP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WGI

Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

PharVision Advisers's BAP Position: Q4 2025 in Review

PharVision Advisers sold out of Credicorp (BAP) in Q4 2025, closing a stake of 1,045 shares — an estimated $278K sold.

PharVision Advisers first reported a position in BAP in Q3 2025 and held it in 1 quarter. The position peaked at $278K in Q3 2025. 402 funds tracked by Wall St. Rank hold BAP as of Q4 2025.

PharVision Advisers reported no remaining Credicorp position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,045 Credicorp shares in Q4 2025, an estimated $278K.
PharVision Advisers first reported a position in Credicorp in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Credicorp position peaked at $278K in Q3 2025.
402 funds tracked by Wall St. Rank held Credicorp as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.